Whittier Trust Co. of Nevada Inc. Reduces Stock Holdings in Eli Lilly and Company $LLY

Whittier Trust Co. of Nevada Inc. reduced its position in Eli Lilly and Company (NYSE:LLY) by 1.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,604 shares of the company’s stock after selling 836 shares during the period. Eli Lilly and Company comprises about 1.0% of Whittier Trust Co. of Nevada Inc.’s portfolio, making the stock its 18th biggest holding. Whittier Trust Co. of Nevada Inc.’s holdings in Eli Lilly and Company were worth $49,589,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Brighton Jones LLC raised its position in Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC raised its position in shares of Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after buying an additional 40 shares during the last quarter. Schnieders Capital Management LLC. raised its position in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after buying an additional 1,141 shares during the last quarter. Flow Traders U.S. LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $356,000. Finally, Nebula Research & Development LLC acquired a new stake in shares of Eli Lilly and Company in the second quarter valued at about $749,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 0.7%

Shares of NYSE:LLY opened at $920.62 on Tuesday. The firm’s 50 day moving average price is $968.67 and its 200 day moving average price is $984.09. The stock has a market cap of $869.82 billion, a price-to-earnings ratio of 40.11, a price-to-earnings-growth ratio of 1.08 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter last year, the company earned $5.32 earnings per share. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 34.7 earnings per share for the current fiscal year.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly announced it will acquire Kelonia Therapeutics to add an in‑vivo CAR‑T/gene‑delivery platform (KLN‑1010) that could materially expand its oncology pipeline and long‑term growth optionality. Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
• Positive Sentiment: UBS kept a Buy rating and $1,250 price target on LLY after the deal, signaling analyst confidence that the acquisition enhances Lilly’s growth runway. Eli Lilly: Kelonia Acquisition Expands Next‑Gen In‑Vivo CAR‑T Platform and Supports Buy Rating
• Positive Sentiment: Consensus analyst stance remains constructive (reported as a “Moderate Buy”), which supports buy‑side interest despite near‑term volatility. Eli Lilly and Company (NYSE:LLY) Receives Consensus Recommendation of “Moderate Buy” from Analysts
• Neutral Sentiment: The deal structure: $3.25B upfront with up to $7B total via milestones — strategic for pipeline but large enough to attract scrutiny on near‑term cash/deal economics. Eli Lilly to acquire Kelonia in $7 billion cancer therapy push
• Neutral Sentiment: Media/industry reports tracked the deal’s progression over the weekend and Monday, so some price moves reflect news flow timing rather than a change in fundamentals. Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says
• Negative Sentiment: Investors expressed caution about the timing/size of the deal as a hedge against potential GLP‑1 revenue normalization — some coverage framed the move as diversification away from high GLP‑1 reliance. Eli Lilly hedges for a GLP-1 revenue drop-off with $7B acquisition
• Negative Sentiment: Regulatory headlines add pressure: the FDA has requested additional data on Lilly’s newly approved obesity (GLP‑1) pill related to potential liver injury and post‑marketing cardiovascular studies, creating short‑term uncertainty. Eli Lilly (LLY) Says FDA Requests Additional Data on Obesity Pill
• Negative Sentiment: Some outlets noted an immediate negative price reaction as the Kelonia deal details emerged, reflecting investor wariness about pay‑up risk and near‑term dilution of focus/capital. Eli Lilly Stock Falls as It Closes in on a $2 Billion Deal. Here’s Why.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Daiwa Securities Group increased their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday, March 6th. Berenberg Bank increased their price target on shares of Eli Lilly and Company from $950.00 to $1,050.00 and gave the stock a “hold” rating in a research report on Thursday, February 19th. Finally, JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,224.59.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.